Immix Biopharma said on Sept. 30, 2026, that it had closed its previously announced underwritten registered offering of 11,363,637 shares of common stock at a public offering price of $11.00 a share, with net proceeds of about $117.1 million after underwriting discounts, commissions and other offering expenses.

The company said it intends to use the proceeds to fund development of NXC-201, along with working capital and general corporate purposes. J.P. Morgan acted as sole book-running manager for the offering, which included participation from U.S. biotechnology institutional investors and mutual funds.

Immix said the shares were sold under a shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission on Jan. 9, 2026 and declared effective on Jan. 22, 2026. It also said a prospectus supplement and accompanying prospectus were filed with the SEC and are available on the regulator’s website.

Highlights

  • The company sold 11,363,637 common shares at $11.00 each.
  • Net proceeds were approximately $117.1 million after expenses.
  • Immix said it plans to use the money for NXC-201 development, working capital and general corporate purposes.